GEORGE LOUIS BAKRIS

Summary

Country: USA

Publications

  1. ncbi Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
  2. ncbi Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
  3. pmc Slowing nephropathy progression: focus on proteinuria reduction
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin J Am Soc Nephrol 3:S3-10. 2008
  4. ncbi Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action
    G Bakris
    Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Hum Hypertens 22:63-70. 2008
  5. ncbi Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial
    G L Bakris
    Department of Medicine, Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Kidney Int 72:879-85. 2007
  6. ncbi Current perspectives on hypertension and metabolic syndrome
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 USA
    J Manag Care Pharm 13:S3-5. 2007
  7. ncbi Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study
    G Bakris
    Department of Preventive Medicine, Rush University Hypertension Center, Chicago, IL, USA
    J Hum Hypertens 21:347-52. 2007
  8. ncbi Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
  9. ncbi Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:27-32. 2008
  10. ncbi Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005

Research Grants

  1. AASK Cohort Study
    George Bakris; Fiscal Year: 2007

Collaborators

Detail Information

Publications67

  1. ncbi Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
    ..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
  2. ncbi Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  3. pmc Slowing nephropathy progression: focus on proteinuria reduction
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin J Am Soc Nephrol 3:S3-10. 2008
    ..These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits...
  4. ncbi Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action
    G Bakris
    Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Hum Hypertens 22:63-70. 2008
    ..These actions should be pursued with vigour in accordance with current clinical guidelines, with the details of implementation adapted to the economic and cultural setting...
  5. ncbi Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial
    G L Bakris
    Department of Medicine, Hypertension Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Kidney Int 72:879-85. 2007
    ..Our results suggest that patients with cardiovascular risk and relatively low albumin excretion rates in early-stage disease may only require monotherapy with renin-angiotensin-aldosterone blocking agents...
  6. ncbi Current perspectives on hypertension and metabolic syndrome
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637 USA
    J Manag Care Pharm 13:S3-5. 2007
    ..Cardiovascular disease (CVD), which affects 79.4 million Americans, is a relentless problem that continues to grow by leaps and bounds...
  7. ncbi Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study
    G Bakris
    Department of Preventive Medicine, Rush University Hypertension Center, Chicago, IL, USA
    J Hum Hypertens 21:347-52. 2007
    ..5 beats per minute, placebo). No adverse effects were recorded. We conclude that restoration of Atlas alignment is associated with marked and sustained reductions in BP similar to the use of two-drug combination therapy...
  8. ncbi Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
    ..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
  9. ncbi Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:27-32. 2008
    ..The combination of amlodipine and an angiotensin II receptor blocker is well tolerated, including in patients with stage 2 hypertension and the elderly...
  10. ncbi Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  11. ncbi Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study
    George Bakris
    University of Chicago Pritzker School of Medicine, Chicago, IL 60612, USA
    J Cardiometab Syndr 3:18-25. 2008
    ..0 vs 7.2+/-2.3; P<.001). This exploratory study suggests that the impairment in glycemic control seen with use of a thiazide diuretic combined with a RASI can be reversed by switching to a regimen that does not include a diuretic...
  12. doi Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study
    G L Bakris
    Hypertensive Diseases Unit, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Kidney Int 73:1303-9. 2008
    ..The dissociation between reductions in blood pressure and albuminuria may be related to factors other than blood pressure...
  13. ncbi Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Am J Cardiol 98:46L-52L. 2006
    ..These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors...
  14. ncbi Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers
    George L Bakris
    University of Chicago School of Medicine, Department of Medicine, Hypertensive Diseases Unit, Chicago, Illinois 60637, USA
    Am J Cardiovasc Drugs 7:25-9. 2007
    ....
  15. doi Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  16. ncbi A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  17. ncbi Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  18. doi Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  19. ncbi The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension
    Janice Lea
    Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
    Arch Intern Med 165:947-53. 2005
    ..The objective of this study was to relate baseline and early changes in proteinuria and glomerular filtration rate (GFR) to long-term progression of hypertensive nondiabetic kidney disease...
  20. ncbi Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study
    George L Bakris
    Rush Medical University, 1700 W Van Buren St, Suite 470, Chicago, IL
    Hypertension 44:637-42. 2004
    ..Thus, a verapamil SR-based antihypertensive treatment strategy is an alternative to a beta-blocker-based strategy in adults with CAD and diabetes...
  21. ncbi Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  22. ncbi The current state of RAAS blockade in the treatment of hypertension and proteinuria
    Rigas G Kalaitzidis
    Hypertension Diseases Unit, University of Chicago Pritzker School of Medicine, MC1027, Room P 328A, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Cardiol Rep 11:436-42. 2009
    ..Increases in proteinuria, in spite of blood pressure reduction, are associated with faster declines in kidney function regardless of whether RAAS blockers are used...
  23. ncbi Evaluation and treatment of patients with systemic hypertension
    Jay Garg
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Circulation 105:2458-61. 2002
  24. ncbi Clinical importance of microalbuminuria in diabetes and hypertension
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 6:352-6. 2004
    ..Further lowering of albuminuria may be achieved by adding verapamil, diltiazem, or an ARB to an ACE inhibitor...
  25. doi Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Curr Opin Nephrol Hypertens 18:386-91. 2009
    ....
  26. ncbi Diabetes and chronic kidney disease: tragedy and challenge
    Dave Y Chua
    Department of Preventive Medicine, Rush University Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Blood Purif 22:130-5. 2004
    ....
  27. ncbi Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
    ..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies...
  28. doi Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP)
    Rigas Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Kidney Dis 53:S22-31. 2009
    ..Chronic kidney disease (CKD) is a worldwide public health problem. Systolic blood pressure as an associated feature of CKD has not been fully explored in community volunteer and nationally representative samples of the US population...
  29. doi Fixed-dose combination and chronic kidney disease progression: which is the best?
    Keith A Hopkins
    Hypertensive Diseases Unit, Department of Medicine, The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Curr Opin Nephrol Hypertens 19:450-5. 2010
    ..Use of combination therapy whether fixed dose or separate pill combinations is becoming more prevalent. Physicians are not routinely trained in using combinations of different antihypertensive medicines...
  30. ncbi The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  31. ncbi Who should be treated with combination therapy as initial treatment for hypertension?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:21-8. 2003
    ....
  32. ncbi Blood pressure control and nephroprotection in diabetes
    Kevin Abbott
    Walter Reed Army Hospital, Department of Medicine, Division of Nephrology, Bethesda, Maryland, USA
    J Clin Pharmacol 44:431-8. 2004
    ..Physicians need to work harder and educate patients on the importance of achieving these lower blood pressure guidelines...
  33. ncbi Protecting renal function in the hypertensive patient: clinical guidelines
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:112S-119S. 2005
    ..This is achieved optimally by using agents that block the renin-angiotensin system in concert with other agents that reduce proteinuria and BP...
  34. ncbi Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
    George L Bakris
    University of Chicago, IL, USA
    Prev Cardiol 11:42-9. 2008
    ..The authors maintained full control of the discussion and the resulting content of this article...
  35. ncbi Comparative efficacy of two different beta-blockers on 24-hour blood pressure control
    Pantelis Sarafidis
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 10:112-8. 2008
    ..It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-hour period...
  36. doi Effects of angiotensin II receptor blockers on diabetic nephropathy
    Rigas Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    J Hypertens Suppl 27:S15-21. 2009
    ....
  37. doi The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    J Hypertens 27:666-9. 2009
    ..Therefore, treatment of hypertension has become the most important intervention in the management of all forms of CKD. For this reason, the forthcoming World Kidney Day on 12 March 2009 will emphasize the role of hypertension...
  38. ncbi Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:202-9. 2003
    ..A fixed-dose combination approach appears as safe as the current conventional approaches...
  39. doi Hypertension goals in advanced-stage kidney disease
    Keith Hopkins
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 4:S92-4. 2009
    ..Aggressive volume control seems key to maintaining good BP control. Once a valid time and measure for BP is agreed on, a clinical outcome trial is needed to test its utility...
  40. ncbi The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols
    George L Bakris
    Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 113:35-40, 43-4, 50. 2003
    ..He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes...
  41. doi Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010
    ..The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events...
  42. ncbi The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial
    George L Bakris
    Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
    J Diabetes Complications 19:74-9. 2005
    ..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension...
  43. ncbi Antihypertensive therapy in the presence of proteinuria
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
    Am J Kidney Dis 49:12-26. 2007
    ....
  44. doi Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP)
    Andrew S Bomback
    Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, 622 W 168th Street, New York, NY 10032, USA
    Am J Kidney Dis 55:S4-S14. 2010
    ....
  45. ncbi The role of calcium antagonists in chronic kidney disease
    Casey N Gashti
    Rush University Hypertension Clinical Research Centre, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Centre, Chicago, Illinois 60612, USA
    Curr Opin Nephrol Hypertens 13:155-61. 2004
    ..To review goals of antihypertensive treatment in chronic kidney disease in the context of what role calcium antagonists play toward reducing progression of kidney disease...
  46. ncbi Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction
    George L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 2:258-62. 2002
    ..In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke...
  47. ncbi Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 8:604-11. 2010
    ..Thus, concomitant evaluation of both biomarkers eGFR and albuminuria is recommended to assess kidney function and CV risk thoroughly...
  48. doi Predictors of hyperkalemia risk following hypertension control with aldosterone blockade
    Nitin Khosla
    Department of Medicine, Section of Nephrology and Hypertension, University of California at San Diego, San Diego, CA, USA
    Am J Nephrol 30:418-24. 2009
    ..This study assesses the risk factors for hyperkalemia in patients with chronic kidney disease (CKD) and resistant hypertension whose blood pressure (BP) is reduced to a guideline goal...
  49. doi Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Postgrad Med 121:51-60. 2009
    ..This article also presents an approach to managing increases in creatinine and potassium that should fit comfortably in the hands of primary care clinicians...
  50. ncbi ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 4:420-3. 2002
    ..This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes...
  51. doi Dual RAAS blockade is desirable in kidney disease: con
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Kidney Int 78:546-9. 2010
    ..In all cases other than advanced proteinuric nephropathy, there is no evidence of any positive CKD outcome with dual RAAS blockade. Thus, dual RAAS blockade cannot be recommended for all CKD patients...
  52. ncbi Achieving blood pressure goals: is fixed-dose combination therapy the answer?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:2-3. 2003
  53. doi Predictors of hypertension control in a diverse general cardiology practice
    Adam D DeVore
    Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Clin Hypertens (Greenwich) 12:570-7. 2010
    ..In addition, 2 novel predictors of HTN control, recognition of systolic blood pressure goal and knowledge of HTN control, were identified that can be utilized in creating new HTN treatment interventions...
  54. ncbi Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study
    Jay P Garg
    Division of Nephrology, Department of Medicine, University of California San Francisco, USA
    Am J Nephrol 25:393-9. 2005
    ..Because angiotensin II may have adverse effects on the arterial wall, we hypothesized that an angiotensin receptor blocker (ARB) would improve arterial compliance as compared with placebo in subjects with CKD...
  55. ncbi Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)
    Garabed Eknoyan
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Am J Kidney Dis 42:617-22. 2003
  56. ncbi Hypertension and nephropathy
    George L Bakris
    Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Med 115:49S-54S. 2003
    ..In patients with type 2 diabetes, early use of TZDs may be beneficial in both achieving glucose control and reducing the development or worsening of microalbuminuria or hypertension...
  57. ncbi Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics
    Munavvar Izhar
    Rush Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Hypertension 43:573-7. 2004
    ..Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency...
  58. ncbi Management of hypertension in the cardiometabolic syndrome and diabetes
    Nitin Khosla
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 4:199-205. 2004
    ..Thus, treating the cardiometabolic syndrome requires an aggressive approach with a focus on both lifestyle modification and pharmacologic intervention...
  59. ncbi Controlled-release carvedilol in the treatment of essential hypertension
    Michael A Weber
    Department of Medicine, State University of New York Downstate College of Medicine, New York, New York 10170, USA
    Am J Cardiol 98:32L-38L. 2006
    ..We conclude that carvedilol CR is a very effective antihypertensive agent with clear dose-related peak blood pressure reduction and continuous 24-hour control...
  60. doi Lower blood pressure goals in high-risk cardiovascular patients: are they defensible?
    Keith A Hopkins
    The University of Chicago Pritzker School of Medicine, IL 60637, USA
    Cardiol Clin 28:447-52. 2010
    ..Most patients should have their systolic BP reduced to levels well below 140 mm Hg approaching 130 mm Hg, not 140 mm Hg...
  61. ncbi Preventing hypertensive kidney disease: the critical role of combination therapy
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:93S-94S. 2005
  62. ncbi Implications of albuminuria on kidney disease progression
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:18-22. 2004
    ..Use of an angiotensin receptor blocker added to an angiotensin-converting enzyme inhibitor or vice versa can further lower albuminuria by an additional 30%-40%, which is not true of the additional lowering of BP...
  63. pmc Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
    Michael L Maitland
    Department of Medicine, University of Chicago Medical Center, 5841Chicago, IL 60637, USA
    J Natl Cancer Inst 102:596-604. 2010
    ..Proper agent selection, dosing, and scheduling of follow-up should enable maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP...
  64. ncbi Microalbuminuria: what is it? Why is it important? What should be done about it? An update
    Atul Chugh
    Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, IL 60637, USA
    J Clin Hypertens (Greenwich) 9:196-200. 2007
    ..The National Kidney Foundation recommends that blood pressure levels be maintained at or below 130/80 mm Hg in anyone with diabetes or kidney disease...
  65. ncbi Differential effects of calcium antagonist subclasses on markers of nephropathy progression
    George L Bakris
    Rush University Hypertension Center, Chicago, Illinois 60612, USA
    Kidney Int 65:1991-2002. 2004
    ..In an earlier systematic review, calcium antagonists were shown as effective antihypertensive drugs, but there was uncertainty about their renal benefits in patients with proteinuria and renal insufficiency...
  66. doi Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Hypertensive Diseases Unit, Chicago, IL, USA
    Postgrad Med 120:33-42. 2008
    ..Clinical data and ongoing trials will be discussed in the context of this hypothesis...
  67. ncbi Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
    Nitin Khosla
    Department of Preventive Medicine, Rush Hypertension Clinical Research Center, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:354-6. 2005

Research Grants1

  1. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..